Get the Stockscreener App
2.61
3.33%
-0.09
After Hours:
2.60
-0.010
-0.38%
Vivos Therapeutics Inc stock is traded at $2.61, with a volume of 157.71K.
It is down -3.33% in the last 24 hours and down -3.69% over the past month.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
See More
Previous Close:
$2.70
Open:
$2.67
24h Volume:
157.71K
Relative Volume:
0.12
Market Cap:
$8.88M
Revenue:
$14.50M
Net Income/Loss:
$-15.41M
P/E Ratio:
-3.6761
EPS:
-0.71
Net Cash Flow:
$-13.04M
1W Performance:
-10.92%
1M Performance:
-3.69%
6M Performance:
-45.96%
1Y Performance:
+1,259%
1-Day Range:
$2.60
$2.81
1-Week Range:
$2.60
$3.35
52-Week Range:
$0.1801
$48.79
Vivos Therapeutics Inc Stock (VVOS) Company Profile
Name
Vivos Therapeutics Inc
Sector
Industry
Phone
(866)908-4867
Address
7921 SOUTHPARK PLAZA,, LITTLETON
Vivos Therapeutics Inc Stock (VVOS) Latest News
Balance Sheet Insights: Vivos Therapeutics Inc (VVOS)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Stock Market Recap: Vivos Therapeutics Inc (VVOS) Concludes at 3.08, a -4.35 Surge/Decline - The Dwinnex
Vivos surges on FDA nod for pediatric sleep apnea device - MSN
You might want to take a look at Vivos Therapeutics Inc (VVOS) now - SETE News
Vivos Therapeutics announces $4.3 million stock sale By Investing.com - Investing.com Canada
Vivos Therapeutics announces $4.3 million stock sale - Investing.com
VVOS’s price-to-cash ratio: How it affects the stock’s valuation. - US Post News
Vivos Therapeutics Shares Drop 27% After Pricing of Common Stock Offering - MarketWatch
Why Vivos Therapeutics (VVOS) Stock Is Down 25% Today - Benzinga
Vivos Therapeutics announces $4.3 million stock sale By Investing.com - Investing.com Australia
Nasdaq Surges 400 Points; US Jobless Claims Fall To 219,000 - Benzinga
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - StockTitan
Vivos Therapeutics raises $4.3 from institutional investors - Proactive financial news
Nvidia, T-Mobile US, Vivos Therapeutics, SoFi Technologies, Tesla: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Vivos Therapeutics surges on FDA approval for youth sleep apnea treatment device - Mugglehead
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring - ForexTV.com
S&P 500 Industrials [Sector] (SRIN) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
TSX 60 Equal Weight Index (TXEW) QuotePress Release - The Globe and Mail
TSX Metals and Mining Capped Index (TTMN) QuotePress Release - The Globe and Mail
TSX Cannabis Index (XCAN) QuotePress Release - The Globe and Mail
Company’s Banking Shares: Up -92.74% from 52-Week Low, But Can the Momentum Hold? - The InvestChronicle
Vivos surges on FDA nod for pediatric sleep apnea device - Seeking Alpha
Vivos Therapeutics rises on FDA approval for pediatric sleep apnea device - XM
What's Going On With TG Therapeutics Stock Wednesday? - Benzinga
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children - Benzinga
Vivos Therapeutics Shares Rally on FDA Clearance for Pediatric Sleep Apnea Treatment - MarketWatch
Vivos Therapeutics’ oral device approved by FDA for pediatric sleep apnea treatment - Proactive Investors UK
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Vivos (VVOS) Stock Rallies In Pre-Hours Trading Following Key Regulatory Approval - Stocks Telegraph
Vivos gains FDA nod for child OSA treatment device - Investing.com
Vivos receives FDA 510k clearance to treat pediatric sleep apnea, snoring - TipRanks
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring - StockTitan
Target Hospitality Corp. Forecasted to Post FY2025 Earnings of $0.39 Per Share (NASDAQ:TH) - Defense World
Research Analysts Set Expectations for Huntington Ingalls Industries, Inc.’s Q2 2025 Earnings (NYSE:HII) - Defense World
Upbound Group, Inc. (NASDAQ:UPBD) Receives $40.25 Consensus Price Target from Brokerages - Defense World
Verint Systems Inc. (NASDAQ:VRNT) Short Interest Up 29.6% in August - Defense World
Los Angeles Capital Management LLC Sells 4,000 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Los Angeles Capital Management LLC Grows Position in TPI Composites, Inc. (NASDAQ:TPIC) - Defense World
Vivos Therapeutics announces new equity incentive plan and executive agreements - Investing.com
Vivos Therapeutics Enhances Incentives and Executive Pay Structure - TipRanks
Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story - Simply Wall St
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Update - Defense World
3 Trending Biotech Penny Stocks - 24/7 Wall St.
VVOS Stock Earnings: Vivos Therapeutics Beats EPS, Beats Revenue for Q2 2024 - MSN
Ascendiant sees 180% upside in Vivos Therapeutics shares amid revenue rebound - Investing.com Canada
Earnings call: Vivos Therapeutics sees revenue and enrollment growth - Investing.com India
Earnings call: Vivos Therapeutics sees revenue and enrollment growth - Investing.com
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q2 2024 Earnings Call Transcript - Insider Monkey
Q2 2024 Vivos Therapeutics Inc Earnings Call Transcript - Stockxpo
Vivos Secures Medicare Reimbursement and Launches New Marketing Strategy in Q2 - Sleep Review
Vivos Therapeutics Inc Stock (VVOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
1.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):